Cyclopharm Ltd (CYC) - Total Assets
Based on the latest financial reports, Cyclopharm Ltd (CYC) holds total assets worth AU$49.68 Million AUD (≈ $35.15 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cyclopharm Ltd - Total Assets Trend (2005–2025)
This chart illustrates how Cyclopharm Ltd's total assets have evolved over time, based on quarterly financial data. Also see market cap of Cyclopharm Ltd for the company's overall valuation and market capitalisation.
Cyclopharm Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Cyclopharm Ltd's total assets of AU$49.68 Million consist of 61.7% current assets and 38.3% non-current assets. Review how much debt does Cyclopharm Ltd carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 14.4% |
| Accounts Receivable | AU$8.59 Million | 18.6% |
| Inventory | AU$11.43 Million | 24.8% |
| Property, Plant & Equipment | AU$13.40 Million | 29.1% |
| Intangible Assets | AU$1.70 Million | 3.7% |
| Goodwill | AU$974.61K | 2.1% |
Asset Composition Trend (2005–2025)
This chart illustrates how Cyclopharm Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Cyclopharm Ltd (CYC) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cyclopharm Ltd's current assets represent 61.7% of total assets in 2025, an increase from 61.2% in 2005.
- Cash Position: Cash and equivalents constituted 14.4% of total assets in 2025, down from 41.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 31.0% in 2005.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.1% of total assets.
Cyclopharm Ltd Competitors by Total Assets
Key competitors of Cyclopharm Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Shandong Weigao Orthopaedic Device Co. Ltd. A
SHG:688161
|
China | CN¥5.19 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Ningbo David Medical Device Co Ltd
SHE:300314
|
China | CN¥1.47 Billion |
|
Beijing Succeeder Technology Inc
SHG:688338
|
China | CN¥1.78 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.57 Billion |
|
Profound Medical Corp
TO:PRN
|
Canada | CA$62.28 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
Cyclopharm Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.37 | 3.19 | 9.01 |
| Quick Ratio | 2.17 | 1.94 | 7.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$23.86 Million | AU$24.90 Million | AU$37.57 Million |
Cyclopharm Ltd - Advanced Valuation Insights
This section examines the relationship between Cyclopharm Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.85 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | -25.8% |
| Total Assets | AU$46.10 Million |
| Market Capitalization | $41.81 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cyclopharm Ltd's assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Cyclopharm Ltd's assets decreased by 25.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cyclopharm Ltd (2005–2025)
The table below shows the annual total assets of Cyclopharm Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | AU$46.10 Million ≈ $32.62 Million |
-25.80% |
| 2024-12-31 | AU$62.13 Million ≈ $43.96 Million |
+35.31% |
| 2023-12-31 | AU$45.91 Million ≈ $32.49 Million |
-7.32% |
| 2022-12-31 | AU$49.54 Million ≈ $35.05 Million |
-11.12% |
| 2021-12-31 | AU$55.74 Million ≈ $39.44 Million |
+97.14% |
| 2020-12-31 | AU$28.28 Million ≈ $20.01 Million |
-13.08% |
| 2019-12-31 | AU$32.53 Million ≈ $23.02 Million |
+38.20% |
| 2018-12-31 | AU$23.54 Million ≈ $16.65 Million |
+0.68% |
| 2017-12-31 | AU$23.38 Million ≈ $16.54 Million |
+42.41% |
| 2016-12-31 | AU$16.41 Million ≈ $11.61 Million |
-0.76% |
| 2015-12-31 | AU$16.54 Million ≈ $11.70 Million |
+50.90% |
| 2014-12-31 | AU$10.96 Million ≈ $7.76 Million |
+21.65% |
| 2013-12-31 | AU$9.01 Million ≈ $6.38 Million |
-58.39% |
| 2012-12-31 | AU$21.66 Million ≈ $15.32 Million |
+1.71% |
| 2011-12-31 | AU$21.29 Million ≈ $15.07 Million |
-3.83% |
| 2010-12-31 | AU$22.14 Million ≈ $15.67 Million |
+12.71% |
| 2009-12-31 | AU$19.64 Million ≈ $13.90 Million |
+5.73% |
| 2008-12-31 | AU$18.58 Million ≈ $13.15 Million |
+69.25% |
| 2007-12-31 | AU$10.98 Million ≈ $7.77 Million |
+21.15% |
| 2006-12-31 | AU$9.06 Million ≈ $6.41 Million |
-56.84% |
| 2005-12-31 | AU$20.99 Million ≈ $14.86 Million |
-- |
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more